Equity
€1.1m ▼ 53.5%
ALIGOS BELGIUM paid out €1.5m in dividends. That is 553% of the 2025 profit.
ALIGOS BELGIUM
Lifetime
7 annual accounts with figures on one time axispeak €4.8m (2021)
€3.2m▲ 9.0%
peak €568,356 (2020)
€271,098▲ 0.1%
peak €2.3m (2024)
€1.1m▼ 53.5%
€749,204▼ 23.7%
peak 12.9 FTE (2025)
12.9 FTE▲ 26.5%
Board6 names since 2018
3 directorsLawrence Blatt and 2 others
Owners
consolidatesAligos Therapeutics Inc
Documentsfilings and deeds
02-07-202629 days before the deadline
2025abbreviated format
Staff from 10.2 FTE to 12.9 FTEAppointments: Lesley Calhoun (director) and Sushmita Chanda (… 04-12Resignation: Leonid Beigelman (director) 06-03Dividend €1.5mEquity from €2.3m to €1.1mDebts from €982,500 to €749,204
Key points
from the 2025 annual accountsTurnover
≈ €2.8m estimated
The abbreviated format states no turnover.
Staff
13 employees on 31-12-2025
In 2025, 10 people joined and 9 left.
Liquidity
2.24 was 3.56 in 2024
Short-term debts fell from €877,491 to €728,297.
Filings
7 annual accounts since 2019
The last five annual accounts were filed 3 to 30 days before the end of the period.
Position in the sector
€3.2m
Higher gross margin than 95% of companies in human health. Sector median €280,163 · 2,939 companies.
Checked score
93
Excellent
Financially stronger than 46% of small companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 1,080 companies (NACE 86, small).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%
01-2025: < 0.1%● unchanged vs 12-2024
02-2025: < 0.1%● unchanged vs 01-2025lowest value
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: < 0.1%● unchanged vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: 0.1%▲ +0.1 percentage points vs 09-2026highest value
11-2026: 0.1%● unchanged vs 10-2026highest value
Financial strengthStrong
Score breakdown
raises risk
1 change of registered office in 24 months
lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 2.24, cash €730,848
Figures for financial year 2025 (filed on 02-07-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, small). It does better than 36% of them on solvency, 75% on liquidity, 72% on profitability and 2% on growth.
The bankruptcy probability was computed on 06-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 6,782 companies had the same profile as ALIGOS BELGIUM has now. Each dot stands for 17 companies, two years later.
96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
That fits the bankruptcy probability of ALIGOS BELGIUM itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,782 companies, not a prediction for ALIGOS BELGIUM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €95,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 2.24 (3.56 in 2024), above the usual 1.5. Short-term debt is 40.1% and cash 40.3% of total assets. 41.3% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-07-2026, 29 days ahead of the deadline.
NBB · 7 filingsDeviation from the deadline
2025
29 days early
2024
30 days early
2023
5 days early
2022
6 days early
2021
3 days early
2020
9 days early
2019
9 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 13 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 25 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
07-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered office moved within Leuven
New registered office: Gaston Geenslaan 2, 3001 Leuven · Previous registered office: Gaston Geenslaan 1, 3001 Leuven (Heverlee), België · Board meeting of 18-08-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0702969886
Appointments: Lesley Calhoun (director) and Sushmita Chanda (day-to-day manager)
General meeting of 25-07-2025 · Gazette deed
Resignation: Leonid Beigelman (director)
Appointment: Lawrence Blatt (director) · General meeting of 18-03-2024 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ALIGOS BELGIUM Leuven | €1.8m | €3.2m | 58.7% | 12.9 |
| InnoSer België Diepenbeek | €2.1m | €3.1m | 29.7% | 27.4 |
| EUROFINS FORENSICS BELGIUM Bruges | €3.3m | €3.2m | 9.2% | 24.2 |
| OncoDNA Charleroi | €5.3m | €2.1m | -4.9% | 20.6 |
| Harmony Clinical Research Merelbeke-Melle | €1.6m | €2.1m | 81.8% | - |
| Dokter Fr. Cuigniez - Medische Beeldvorming Ghent | €3.0m | €1.6m | 95.9% | 1.4 |
| Medlab Kortrijk | €1.8m | €1.0m | 26.6% | 3.5 |
These companies have the same main activity as ALIGOS BELGIUM: medical imaging and medical laboratories (NACE 86910). They are comparable in size and age: total assets between €1.6m and €5.3m, founded between 2011 and 2016.
Official details
Source: KBO- Status
- Active since 10-09-2018Normal situation
- Activity
- Medical imaging and medical laboratoriesNACE 86910and 1 other
- Joint committee
- 200Auxiliary committee for white-collar workers · annual accounts 2025
- Establishment unit
- 2.280.023.9963001 Leuven, since 10-09-2018
- Financial year end
- 31 December
- Peppol
- Reachable since 02-01-2026
Annual accounts 2025
- €1.8m▼ 44.6%
- Employeeson 31-12-2025
- 13▲ 8.3%
- Filing
- Filed on 02-07-2026, 29 days before the end of the filing period
Insights on ALIGOS BELGIUM
ALIGOS BELGIUM files the abbreviated format. That format states no turnover. The gross margin fell from €3.3m in 2019 to €3.2m in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ALIGOS BELGIUM
- What is the company number of ALIGOS BELGIUM?
- The company number of ALIGOS BELGIUM is 0702.969.886. The VAT number is the same number with BE in front: BE 0702.969.886.
- Where is ALIGOS BELGIUM based?
- The registered office is at Gaston Geenslaan 2, 3001 Leuven.Company details
- What does ALIGOS BELGIUM do?
- According to the KBO register, the main activity is medical imaging and medical laboratories (NACE 86910).
- What is the legal form of ALIGOS BELGIUM?
- ALIGOS BELGIUM is a private limited company (BV).
- When was ALIGOS BELGIUM founded?
- ALIGOS BELGIUM was founded on 10-09-2018.
- Is ALIGOS BELGIUM still active?
- Yes, ALIGOS BELGIUM is an active enterprise in the KBO register.
- How many employees does ALIGOS BELGIUM have?
- ALIGOS BELGIUM had an average of 12.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does ALIGOS BELGIUM fall under?
- In its 2025 annual accounts, ALIGOS BELGIUM states joint committee 200 (Auxiliary committee for white-collar workers).
- What is the turnover of ALIGOS BELGIUM?
- The turnover in financial year 2025 is ≈ €2.8m. This figure is estimated from the gross margin of €3.2m and 63 comparable companies (NACE 86). It probably lies between €2.6m and €4.2m.
- Is ALIGOS BELGIUM profitable?
- In financial year 2025, ALIGOS BELGIUM made a profit of €271,098.
- Where can I find the annual accounts of ALIGOS BELGIUM?
- ALIGOS BELGIUM filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ALIGOS BELGIUM due?
- ALIGOS BELGIUM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.